1.A 28-year-old woman presents with galactorrhea, amenorrhea, and a serum prolactin of 187 ng/mL. Pituitary magnetic resonance imaging (MRI) reveals a 7 mm microadenoma. She is started on cabergoline. Which of the following most accurately describes the molecular mechanism by which cabergoline reduces prolactin secretion from lactotroph adenoma cells?
A)Cabergoline binds serotonin 5-HT2B receptors on lactotroph cells, reducing prolactin gene transcription through a Gq-coupled decrease in inositol trisphosphate (IP3) signaling.
B)Cabergoline activates D2 receptors (dopamine receptor subtype 2), which are Gi-coupled receptors that reduce adenylyl cyclase activity, lower intracellular cyclic AMP (cAMP), and thereby inhibit prolactin gene transcription and secretion.
C)Cabergoline blocks the hypothalamo-hypophyseal portal delivery of thyrotropin-releasing hormone (TRH), preventing TRH-driven prolactin release from lactotroph cells.
D)Cabergoline inhibits cytochrome P450 3A4 (CYP3A4) within lactotroph cells, reducing the enzymatic conversion of dopamine precursors to prolactin-stimulating metabolites.
E)Cabergoline acts as a competitive antagonist at pituitary prolactin receptors, blocking autocrine prolactin-driven lactotroph stimulation.
ANSWER: B
Rationale:
Prolactin secretion from pituitary lactotrophs is tonically suppressed by hypothalamic dopamine, which travels via the hypothalamo-hypophyseal portal circulation and activates D2 receptors (D2R) on lactotroph cells. D2R is a Gi-coupled, seven-transmembrane receptor; agonist binding reduces adenylyl cyclase activity, lowers intracellular cAMP, and inhibits prolactin gene transcription, prolactin synthesis, and secretion. Lactotroph adenoma cells in prolactinomas retain D2R expression in the majority of cases, allowing dopamine agonists such as cabergoline to recapitulate this tonic inhibitory signal. Beyond reducing secretion, sustained D2R activation also produces direct antiproliferative effects, resulting in tumor volume reduction in 80 to 90% of patients.
Option A is incorrect because the 5-HT2B receptor is expressed on cardiac valve fibroblasts and mediates cabergoline's valvulopathy risk — it is not the receptor responsible for prolactin suppression and is Gq-coupled rather than Gi-coupled.
Option C is incorrect because cabergoline acts directly at lactotroph D2R; it does not block portal delivery of thyrotropin-releasing hormone (TRH), and while TRH is a physiological prolactin secretagogue, reducing TRH delivery is not cabergoline's mechanism.
Option D is incorrect because cabergoline is a dopamine receptor agonist and does not act through CYP3A4 inhibition within lactotroph cells; CYP3A4 is relevant to cabergoline's own hepatic metabolism, not its pharmacodynamic mechanism.
Option E is incorrect because cabergoline is a dopamine receptor agonist, not a prolactin receptor antagonist; prolactin receptors mediate systemic prolactin effects at target tissues, not the primary feedback loop governing secretion.
2.A 35-year-old man presents with decreased libido, visual field deficits, and a large pituitary mass measuring 28 mm on MRI. His serum prolactin returns at 42 ng/mL — only mildly elevated. The radiologist suggests the mass may be a non-functioning adenoma. Which of the following is the most appropriate next diagnostic step to correctly characterize this lesion?
A)Proceed directly to transsphenoidal surgery, as a normal prolactin level with a large pituitary mass confirms a non-functioning adenoma that will not respond to dopamine agonist therapy.
B)Obtain a repeat MRI with gadolinium contrast at higher resolution, as the mildly elevated prolactin likely reflects stalk compression from a non-functioning adenoma rather than a prolactinoma.
C)Measure urinary free prolactin over 24 hours, as serum prolactin is unreliable in large masses due to renal clearance of monomeric prolactin.
D)Request a serial dilution of the serum sample (1:100 dilution) to evaluate for the hook effect, as extremely high prolactin concentrations can saturate the immunometric assay and produce a falsely low result.
E)Order a serum macroprolactin level, as the predominant form of prolactin in large adenomas is the big-big prolactin isoform, which is not detected by standard immunoassay.
ANSWER: D
Rationale:
The hook effect is a critical diagnostic pitfall in the evaluation of large pituitary masses with unexpectedly normal or only mildly elevated serum prolactin. In patients with very large macroprolactinomas, extremely high prolactin concentrations can saturate both the capture and detection antibodies in standard two-site immunometric assays, preventing signal formation and producing a falsely low or even normal reading. The result can mislead the clinician into attributing a large pituitary mass to a non-functioning adenoma, leading to unnecessary surgery. The correct maneuver is to request a serial dilution — specifically a 1:100 dilution — of the serum; true prolactin values will increase proportionally on dilution if the hook effect is present, unmasking the macroprolactinoma. A confirmed macroprolactinoma then warrants dopamine agonist therapy rather than primary surgery.
Option A is incorrect because proceeding directly to surgery without investigating the hook effect risks operating on what is actually a macroprolactinoma — a lesion that would respond to cabergoline with prolactin normalization and tumor shrinkage, making surgery avoidable.
Option B is incorrect because repeat MRI adds no information about the prolactin assay artifact; it would confirm the tumor size but would not resolve the discordance between mass size and prolactin level.
Option C is incorrect because urinary free prolactin is not a validated clinical tool for evaluating pituitary adenoma type, and renal clearance of monomeric prolactin is not the mechanism behind the falsely low serum result in this scenario.
Option E is incorrect because macroprolactin (big-big prolactin, typically IgG-bound prolactin) is associated with elevated, not normal or low, immunoassay results; macroprolactinemia is characterized by a high measured prolactin that overestimates biologically active prolactin, which is the opposite of the hook effect.
3.A 44-year-old woman with a macroprolactinoma has been receiving cabergoline 1.5 mg per week for 6 years with excellent prolactin control. Routine cardiac surveillance reveals mild tricuspid regurgitation with leaflet thickening on echocardiography. Which of the following best explains the mechanism by which cabergoline produces cardiac valvulopathy?
A)Cabergoline activates serotonin 5-HT2B receptors on cardiac valve fibroblasts, stimulating fibroblast proliferation and collagen deposition that produce valve leaflet thickening and regurgitation; this is a non-D2R effect unrelated to the therapeutic prolactin-lowering mechanism.
B)Cabergoline activates D2 receptors (D2R) on cardiac valve fibroblasts; the same Gi-coupled receptor mechanism responsible for prolactin suppression also drives valve fibrosis when receptor activation is sustained over years of treatment.
C)Cabergoline is metabolized by CYP3A4 to a reactive quinone intermediate that accumulates in valve leaflets and triggers a local inflammatory reaction, causing fibrosis through a metabolite-mediated mechanism.
D)Cabergoline activates alpha-1 adrenergic receptors on aortic valve fibroblasts, producing asymmetric fibrosis predominantly affecting the left-sided cardiac valves at doses used for prolactinoma.
E)Cabergoline's valvulopathy results from its structural similarity to ergotamine, which causes direct endothelial injury in cardiac valve leaflets through vasoconstriction of vasa vasorum supplying valve tissue.
ANSWER: A
Rationale:
Cabergoline-associated valvulopathy is mediated by agonist activity at serotonin 5-HT2B receptors expressed on cardiac valve interstitial fibroblasts. 5-HT2B receptor activation stimulates fibroblast proliferation and excess collagen synthesis, producing the fibromyxoid thickening of valve leaflets and regurgitation that characterizes ergot-related valvulopathy. Critically, this is a non-D2R effect — it is entirely separate from the D2R-mediated mechanism responsible for prolactin suppression and tumor volume reduction. This distinction is clinically important because drugs with D2R agonism but without 5-HT2B activity would not carry the same valvulopathy risk. The risk at prolactinoma doses (typically 0.5 to 3.5 mg per week) appears substantially lower than at Parkinson disease doses (often 3 to 6 mg per day), but European guidelines recommend baseline and periodic echocardiographic surveillance, particularly above 2 mg per week.
Option B is incorrect because valvulopathy is not a D2R-mediated effect; D2R activation at the pituitary is responsible for the therapeutic benefit, while 5-HT2B activation at the valve is responsible for the adverse structural change — these are pharmacologically distinct receptor pathways.
Option C is incorrect because cabergoline valvulopathy is a receptor-mediated pharmacodynamic effect at the 5-HT2B receptor, not a reactive metabolite-driven inflammatory process; no quinone intermediate from CYP3A4 metabolism of cabergoline has been implicated in its cardiac effects.
Option D is incorrect because cabergoline does not produce clinically relevant alpha-1 adrenergic receptor agonism at therapeutic doses, and left-sided valve predominance is not a feature of cabergoline valvulopathy, which primarily affects the tricuspid and mitral valves.
Option E is incorrect because while cabergoline is an ergot derivative and shares structural features with ergotamine, the valvulopathy mechanism is specifically 5-HT2B receptor-mediated fibrosis rather than endothelial injury from vasoconstriction of vasa vasorum.
4.A 31-year-old woman with a microprolactinoma has been receiving cabergoline 0.5 mg twice weekly with normalization of prolactin and resumption of regular menses. She now wishes to attempt pregnancy. She has no contraindications to either dopamine agonist. Which of the following best describes current clinical practice regarding dopamine agonist selection at this point in her management?
A)Cabergoline should be continued throughout pregnancy because its longer half-life provides more stable prolactin suppression during the physiological prolactin rise of gestation, reducing the risk of tumor expansion.
B)Both cabergoline and bromocriptine are formally contraindicated in the first trimester of pregnancy, and dopamine agonist therapy must be discontinued before conception is attempted in all patients with microadenomas.
C)Many centers switch from cabergoline to bromocriptine at this stage, or discontinue dopamine agonists once pregnancy is confirmed in microadenoma patients, because bromocriptine has a substantially longer and larger pregnancy safety database spanning over four decades of fertility treatment use.
D)Cabergoline should be replaced with quinagolide, a non-ergot D2R agonist, as it is the only dopamine agonist with prospective safety data in the first trimester derived from a randomized controlled trial in hyperprolactinemic women.
E)Because microadenomas rarely expand during pregnancy, dopamine agonist therapy should be maintained at the lowest effective dose of whichever agent is currently in use, without switching agents, to minimize the risk of hormonal fluctuation during periconception.
ANSWER: C
Rationale:
When a woman with hyperprolactinemia due to a microadenoma wishes to conceive, the choice of dopamine agonist and the question of whether to continue therapy through pregnancy requires consideration of the relative safety databases. Bromocriptine has been used for fertility treatment in hyperprolactinemic women for over four decades, with extensive reassuring data on first-trimester exposure accumulated across thousands of pregnancies; this constitutes the longest and largest pregnancy safety record of any dopamine agonist. Cabergoline is also considered low risk in pregnancy, but its safety database is smaller and accrued over a shorter period. Current practice in many centers is to switch women planning pregnancy from cabergoline to bromocriptine before conception, or to discontinue dopamine agonists entirely once pregnancy is confirmed in patients with microadenomas — the latter being reasonable because microadenomas carry a low risk of symptomatic expansion during pregnancy (approximately 2 to 3%).
Option A is incorrect because cabergoline is not the preferred agent in pregnancy; the rationale for switching to bromocriptine is not pharmacokinetic stability but rather bromocriptine's longer safety record; extended half-life is not an advantage in this context.
Option B is incorrect because neither dopamine agonist is formally contraindicated in pregnancy; both are used when clinically necessary (particularly in macroprolactinoma patients with mass effect risk), and the decision is individualized rather than a blanket contraindication.
Option D is incorrect because quinagolide does not have a randomized controlled trial safety dataset in human pregnancy; it is actually considered to have less pregnancy safety data than bromocriptine and is generally avoided in the periconception period.
Option E is incorrect because it fails to recognize the pharmacological rationale for switching agents; the recommendation to consider bromocriptine is based on comparative safety databases, not on avoiding agent changes.
5.A 38-year-old woman with a microadenoma has been receiving cabergoline for 3 years. Her prolactin has been normal for the past 26 months, and her most recent pituitary MRI shows no visible tumor. She asks about stopping cabergoline. Which of the following best describes the appropriate candidacy criteria and expected outcome for drug withdrawal in this clinical scenario?
A)Cabergoline withdrawal is not recommended until the patient has completed at least 5 years of therapy, as recurrence rates remain above 80% in the first 5 years regardless of MRI findings.
B)Withdrawal is appropriate only in patients with microadenomas who have never required dose escalation above 0.5 mg twice weekly, as higher doses indicate tumor aggressiveness that predicts prolactin recurrence after discontinuation.
C)A 6-month taper of cabergoline is required before discontinuation; abrupt withdrawal carries a risk of acute hyperprolactinemia and tumor rebound that mandates a structured dose reduction protocol in all patients.
D)Withdrawal is appropriate for both microadenoma and macroprolactinoma patients equally, as recurrence rates are similar between tumor sizes and are not influenced by the presence of residual tumor on MRI at the time of withdrawal.
E)This patient meets withdrawal candidacy criteria: prolactin normalized for at least 2 consecutive years and no visible tumor on MRI. Approximately 65 to 70% of such patients remain normoprolactinemic at 1 year after withdrawal; however, recurrence rates reach approximately 30 to 35% within 1 year and up to 70% at 5 years overall, necessitating prolactin monitoring at 1, 3, and 6 months after stopping, then annually.
ANSWER: E
Rationale:
The standard candidacy criteria for cabergoline withdrawal in prolactinoma are: prolactin normalized for at least 2 consecutive years of therapy, and pituitary MRI showing no visible tumor or at most minimal residual changes. This patient satisfies both criteria with 26 months of normoprolactinemia and a clear MRI. Among eligible patients who withdraw, approximately 65 to 70% remain normoprolactinemic at 1 year; however, recurrence rates are approximately 30 to 35% within 1 year and climb to approximately 70% at 5 years. Post-withdrawal monitoring consists of prolactin measurement at 1, 3, and 6 months, then annually, with reinstitution of cabergoline if recurrence is confirmed (response is generally preserved on rechallenge). Patients with macroprolactinomas or persistent radiological tumor carry higher recurrence risk and usually require indefinite therapy. The taper over 2 to 4 months is recommended rather than abrupt discontinuation.
Option A is incorrect because the threshold for withdrawal candidacy is 2 years of sustained normoprolactinemia combined with a clear MRI, not a mandatory 5-year treatment duration; the 5-year figure pertains to recurrence rates after withdrawal, not to a minimum treatment prerequisite.
Option B is incorrect because candidacy for withdrawal is based on duration of normoprolactinemia and MRI findings, not on prior peak dose; dose escalation history does not independently predict recurrence after successful normalization.
Option C is incorrect because while a gradual taper over 2 to 4 months is preferred over abrupt discontinuation, a 6-month taper is not the standard recommendation and acute tumor rebound is not the primary safety concern — the main risk is gradual prolactin recurrence, which is managed by monitoring rather than taper length.
Option D is incorrect because recurrence risk after withdrawal is not equal between microadenoma and macroprolactinoma patients; macroprolactinomas and tumors with persistent MRI changes carry substantially higher recurrence risk and are generally managed with indefinite therapy.
6.A 33-year-old woman with a 14 mm macroprolactinoma has failed to normalize prolactin despite 18 months of cabergoline at 3.5 mg per week — the maximum tolerated dose. Repeat MRI shows less than 20% tumor volume reduction. Which of the following best describes the mechanism most commonly responsible for dopamine agonist resistance in prolactinoma?
A)Resistance is caused by acquired mutations in the D2 receptor (D2R) gene that alter the ligand-binding domain, preventing cabergoline from occupying the receptor at therapeutic plasma concentrations.
B)Resistance most commonly results from reduced D2R protein expression in the tumor — the D2R gene is typically intact, but post-transcriptional or epigenetic mechanisms decrease receptor protein levels, reducing the density of functional D2R available for cabergoline binding.
C)Resistance occurs because cabergoline induces upregulation of adenylyl cyclase isoforms in lactotroph adenoma cells, compensating for the Gi-coupled cAMP reduction and restoring prolactin secretion despite continued D2R occupancy.
D)Resistance is explained by the development of cabergoline-specific antibodies that neutralize the drug before it reaches the pituitary, a mechanism analogous to biologic drug immunogenicity; switching to bromocriptine bypasses this immune barrier.
E)Resistance arises because large macroprolactinomas develop autonomous prolactin secretion through calcium-independent exocytosis pathways that are not regulated by cAMP and therefore cannot be suppressed by D2R activation regardless of receptor expression levels.
ANSWER: B
Rationale:
Dopamine agonist resistance in prolactinoma, defined as failure to normalize prolactin or achieve at least 50% tumor volume reduction at maximally tolerated doses, occurs in approximately 10 to 15% of patients receiving cabergoline. The molecular basis in most resistant tumors is reduced D2R protein expression: the D2R gene sequence is typically intact, but post-transcriptional or epigenetic mechanisms — including altered mRNA stability, promoter methylation, or reduced translation — result in decreased receptor protein density on lactotroph adenoma cells. With fewer functional D2R available, even full receptor occupancy by cabergoline is insufficient to produce the degree of cAMP suppression required for prolactin normalization and tumor regression. Resistance is more common with larger and more invasive tumors. Management options for complete resistance include dose escalation within the tolerated range for partial resistance, transsphenoidal surgery, or temozolomide for aggressive or malignant pituitary tumors.
Option A is incorrect because acquired D2R gene mutations altering the ligand-binding domain are not the established mechanism of cabergoline resistance in clinical prolactinoma; the D2R gene is typically intact in resistant tumors, distinguishing resistance from the acquired mutation mechanisms seen in, for example, EGFR-targeted therapies in oncology.
Option C is incorrect because compensatory adenylyl cyclase upregulation is not the described or predominant mechanism of cabergoline resistance; the primary issue is insufficient D2R density, not downstream signal compensation.
Option D is incorrect because neutralizing antibodies against small-molecule ergot alkaloids such as cabergoline are not a recognized clinical phenomenon; drug immunogenicity of this type is specific to biologic agents such as monoclonal antibodies and fusion proteins, not small organic molecules.
Option E is incorrect because calcium-independent exocytosis producing D2R-insensitive autonomous secretion is not the established mechanism; prolactin secretion in resistant prolactinomas remains partially cAMP-dependent, and the central defect is at the level of receptor expression rather than downstream secretory machinery.
7.A 52-year-old man with acromegaly has been receiving octreotide long-acting release (LAR) at maximum dose for 9 months. His insulin-like growth factor-1 (IGF-1) remains elevated at 1.8 times the upper limit of normal, and his serum prolactin is 62 ng/mL (elevated above the normal male range). Surgery achieved only partial debulking of a 22 mm somatotroph adenoma. The endocrinology team considers adding cabergoline to his somatostatin analog (SSA) regimen. Which of the following best explains why elevated serum prolactin in this patient increases the likelihood of a cabergoline response?
A)regimen. Which of the following best explains why elevated serum prolactin in this patient increases the likelihood of a cabergoline response? A) Elevated prolactin in acromegaly indicates secondary hypogonadism from pituitary stalk compression, and cabergoline lowers prolactin by a stalk-decompression mechanism that simultaneously reduces growth hormone (GH) output through improved portal dopamine delivery.
B)Elevated prolactin indicates that the adenoma has outgrown its blood supply and is undergoing central necrosis; cabergoline reduces tumor size by accelerating this necrotic process through D2R-mediated induction of apoptosis in hypoxic cells.
C)Elevated prolactin reflects increased somatostatin receptor subtype 2 (SSTR2) expression in the adenoma, which predicts enhanced sensitivity to both SSA therapy and the somatostatin-potentiating effect of cabergoline.
D)Elevated prolactin in a somatotroph adenoma suggests co-secretion of prolactin and GH from a mixed lactosomatotroph tumor that expresses D2 receptors (D2R) at levels sufficient to respond to cabergoline; tumors with elevated prolactin have a higher likelihood of D2R expression and thus a higher probability of GH and IGF-1 reduction with dopamine agonism.
E)Elevated prolactin indicates that the tumor is predominantly a prolactinoma with secondary GH excess rather than a true somatotroph adenoma, and cabergoline will normalize prolactin and growth hormone simultaneously by acting on the dominant lactotroph component.
ANSWER: D
Rationale:
In acromegaly, dopamine agonists produce weaker GH suppression than somatostatin analogs because most somatotroph adenomas predominantly express SSTR2 and SSTR5 rather than D2R (dopamine receptor subtype 2). However, a subset of somatotroph adenomas are mixed lactosomatotroph tumors that co-secrete both GH and prolactin; these tumors express D2R at levels sufficient to respond to cabergoline. Elevated serum prolactin in a patient with acromegaly is therefore a practical clinical marker suggesting D2R expression on the adenoma, and published series confirm that patients with elevated prolactin or mildly elevated IGF-1 have a higher likelihood of IGF-1 improvement with cabergoline. Cabergoline add-on to SSA therapy produces additive IGF-1 reduction in approximately 50 to 60% of patients with partial SSA resistance, particularly in those with elevated prolactin.
Option A is incorrect because the rationale for cabergoline in acromegaly with elevated prolactin is not stalk decompression; elevated prolactin in this context reflects co-secretion by a mixed tumor rather than hyperprolactinemia of disconnection, and the mechanism of GH reduction by cabergoline is direct D2R-mediated suppression on the adenoma, not improved portal dopamine delivery.
Option B is incorrect because tumor necrosis is not the mechanism of cabergoline action in acromegaly; while dopamine agonists do have direct antiproliferative effects on lactotroph cells, tumor ischemia-driven necrosis and D2R-mediated apoptosis in hypoxic cells are not the established mechanism for GH reduction.
Option C is incorrect because elevated prolactin does not correlate with SSTR2 expression; SSTR2 expression is the target of first-generation SSAs, and cabergoline acts via D2R, not through somatostatin receptor potentiation.
Option E is incorrect because the scenario describes a somatotroph adenoma with true acromegaly; while mixed tumors co-secrete GH and prolactin, the lesion is not a prolactinoma with secondary GH excess — the dominant clinical syndrome is acromegaly, and the pathology is a GH/prolactin co-secreting somatotroph.
8.A 41-year-old woman with Cushing disease has persistent hypercortisolism following transsphenoidal surgery. Her urinary free cortisol (UFC) remains three times the upper limit of normal. The team initiates pasireotide subcutaneous (SC) 600 mcg twice daily. Which of the following best explains the receptor mechanism responsible for pasireotide's therapeutic effect in Cushing disease?
A)Pasireotide activates somatostatin receptor subtype 5 (SSTR5), which is the predominant somatostatin receptor subtype expressed by corticotroph adenoma cells; SSTR5 activation suppresses adrenocorticotropic hormone (ACTH) secretion from the corticotroph, reducing downstream adrenocortical cortisol production.
B)Pasireotide activates somatostatin receptor subtype 2 (SSTR2), the same receptor targeted by first-generation somatostatin analogs such as octreotide and lanreotide, which is expressed on corticotroph adenoma cells at higher density than SSTR5.
C)remains three times the upper limit of normal. The team initiates pasireotide subcutaneous (SC) 600 mcg twice daily. Which of the following best explains the receptor mechanism responsible for pasireotide's therapeutic effect in Cushing disease? A) Pasireotide activates somatostatin receptor subtype 5 (SSTR5), which is the predominant somatostatin receptor subtype expressed by corticotroph adenoma cells; SSTR5 activation suppresses adrenocorticotropic hormone (ACTH) secretion from the corticotroph, reducing downstream adrenocortical cortisol production. B) Pasireotide activates somatostatin receptor subtype 2 (SSTR2), the same receptor targeted by first-generation somatostatin analogs such as octreotide and lanreotide, which is expressed on corticotroph adenoma cells at higher density than SSTR5. C) Pasireotide blocks glucocorticoid receptors (GR) on corticotroph cells, preventing cortisol from suppressing corticotropin-releasing hormone (CRH) stimulation, paradoxically reducing ACTH by restoring hypothalamic negative feedback.
D)Pasireotide activates dopamine D2 receptors (D2R) on corticotroph adenoma cells through cross-reactivity at the somatostatin receptor binding site, providing a mechanism analogous to cabergoline but derived from a somatostatin analog scaffold.
E)Pasireotide stimulates hypothalamic somatostatin release, increasing portal somatostatin delivery to the anterior pituitary and indirectly suppressing ACTH through increased endogenous somatostatin tone rather than direct pituitary receptor activation.
ANSWER: A
Rationale:
Corticotroph adenoma cells causing Cushing disease predominantly express SSTR5 (somatostatin receptor subtype 5) rather than the SSTR2 subtype that is the principal target of first-generation somatostatin analogs octreotide and lanreotide. Pasireotide is a pan-somatostatin receptor agonist with high-affinity binding to SSTR1, SSTR2, SSTR3, and SSTR5; its therapeutic advantage in Cushing disease derives specifically from its potent SSTR5 agonism, which suppresses ACTH secretion from the corticotroph adenoma. The pivotal phase 3 trial demonstrated UFC normalization in approximately 26 to 35% of Cushing disease patients at 6 months with pasireotide SC 600 to 900 mcg twice daily. A long-acting release (LAR) formulation dosed at 40 to 60 mg intramuscular (IM) monthly produces comparable outcomes.
Option B is incorrect because SSTR2, not SSTR5, is the receptor predominantly targeted by first-generation SSAs; corticotroph adenomas express relatively low SSTR2 density, explaining why octreotide and lanreotide are largely ineffective in Cushing disease — pasireotide's advantage is precisely its SSTR5 affinity, which overcomes this limitation.
Option C is incorrect because pasireotide does not block glucocorticoid receptors; mifepristone is the glucocorticoid receptor antagonist used in Cushing syndrome management, and it operates at target tissues rather than the pituitary to block cortisol signaling.
Option D is incorrect because pasireotide does not activate D2R; it is a somatostatin analog acting at somatostatin receptor subtypes, and its mechanism in corticotroph tumors is distinct from the dopamine agonist mechanism of cabergoline.
Option E is incorrect because pasireotide acts directly on SSTR5 expressed by corticotroph adenoma cells in the pituitary; hypothalamic somatostatin stimulation is not the mechanism of action, and the drug does not require an intact hypothalamic-portal somatostatin axis for its effect.
9.A 55-year-old woman with Cushing syndrome and poorly controlled type 2 diabetes mellitus who failed transsphenoidal surgery is started on mifepristone (Korlym) for management of hyperglycemia. At her 8-week follow-up visit, her fasting glucose and HbA1c have improved substantially, but her serum cortisol is markedly elevated and her adrenocorticotropic hormone (ACTH) level is also high. Which of the following best explains these laboratory findings?
A)The elevated cortisol and ACTH indicate that mifepristone is ineffective — glucocorticoid receptor (GR) blockade has failed to reduce hypothalamic-pituitary-adrenal (HPA) axis activity, and an alternative drug class should be initiated.
B)The elevated cortisol and ACTH reflect paradoxical stimulation of corticotroph tumor growth by mifepristone through a direct pituitary agonist effect, and these findings warrant urgent pituitary MRI to assess for tumor enlargement.
C)The elevated cortisol and ACTH are the expected pharmacodynamic response to mifepristone: because GR blockade eliminates cortisol's negative feedback on the hypothalamus and pituitary, cortisol and ACTH rise as a compensatory response; these biomarkers are not informative for assessing treatment efficacy or adrenal insufficiency — clinical endpoints such as glucose control, blood pressure, and weight are used instead.
D)The elevated cortisol reflects mifepristone's inhibition of cortisol clearance via CYP3A4, which reduces hepatic cortisol metabolism and produces cortisol accumulation independent of HPA axis stimulation.
E)The elevated ACTH indicates that mifepristone has been converted to a glucocorticoid receptor partial agonist in this patient, producing paradoxical cortisol-like stimulation at the corticotroph that drives ACTH hypersecretion as a class effect at high plasma concentrations.
ANSWER: C
Rationale:
Mifepristone is a glucocorticoid receptor (GR) antagonist that blocks cortisol signaling at target tissues, improving the metabolic and clinical consequences of cortisol excess without reducing cortisol secretion itself. Because mifepristone blocks GR-mediated negative feedback at the hypothalamus and pituitary, the normal suppressive effect of cortisol on CRH and ACTH release is abolished, resulting in a compensatory rise in both ACTH and cortisol levels. This is the expected pharmacodynamic response — a rising cortisol does not indicate treatment failure or worsening disease. Critically, serum cortisol, UFC, and ACTH cannot be used to assess mifepristone efficacy or to diagnose adrenal insufficiency in patients on this drug. Treatment adequacy is monitored using clinical and metabolic endpoints: blood glucose control, HbA1c, blood pressure, weight, and resolution of cushingoid features. If adrenal insufficiency is clinically suspected (hypotension, fatigue, hyponatremia), it is diagnosed on clinical grounds and treated empirically with high-dose hydrocortisone, then mifepristone is discontinued to restore normal feedback. In this patient, the improved glucose and HbA1c confirm the drug is working as intended.
Option A is incorrect because the elevated cortisol and ACTH are a predictable result of GR blockade and provide no evidence of therapeutic failure; clinical improvement in glucose control is the appropriate metric, and it confirms efficacy.
Option B is incorrect because direct corticotroph tumor stimulation by mifepristone is not a recognized mechanism; the ACTH elevation results from lost negative feedback at the hypothalamus and pituitary, not from mifepristone binding to pituitary receptors to stimulate tumor growth.
Option D is incorrect because mifepristone is a substrate of CYP3A4 and its metabolism can be affected by CYP3A4 inhibitors, but mifepristone does not inhibit cortisol clearance to a clinically significant degree; the elevated cortisol reflects increased HPA drive, not reduced cortisol catabolism.
Option E is incorrect because mifepristone is a GR antagonist, not a partial agonist, at therapeutic doses; it does not convert to an agonist at the corticotroph, and partial agonist activity producing ACTH hypersecretion is not a recognized class effect of mifepristone.
10.A 47-year-old man with Cushing disease and failed pituitary surgery is started on ketoconazole 400 mg twice daily to reduce cortisol while awaiting radiation treatment effect. Which of the following correctly identifies the primary enzymatic target responsible for ketoconazole's most potent cortisol-lowering effect within the adrenal cortex?
A)Ketoconazole's most potent inhibitory effect is at CYP11B2 (aldosterone synthase), which catalyzes the final steps in aldosterone synthesis; cortisol reduction is a secondary consequence of substrate diversion from glucocorticoid to mineralocorticoid pathways.
B)Ketoconazole most potently inhibits CYP11B1 (11-beta-hydroxylase), which converts 11-deoxycortisol to cortisol in the final step of glucocorticoid synthesis; the upstream enzymes are relatively spared at clinical doses.
C)Ketoconazole inhibits 3-beta-hydroxysteroid dehydrogenase (3β-HSD) as its dominant adrenal enzyme target, blocking the conversion of pregnenolone to progesterone and thereby reducing substrate availability for all downstream steroid hormones including cortisol.
D)as its dominant adrenal enzyme target, blocking the conversion of pregnenolone to progesterone and thereby reducing substrate availability for all downstream steroid hormones including cortisol. D) Ketoconazole's primary cortisol-lowering mechanism is inhibition of CYP11A1 (cholesterol side-chain cleavage enzyme, P450scc), which catalyzes the first committed step in steroidogenesis — conversion of cholesterol to pregnenolone.
E)Ketoconazole inhibits multiple adrenal CYP enzymes including CYP11A1, CYP11B1, and CYP17A1 (17-alpha-hydroxylase/17,20-lyase), with its most potent inhibitory effect at CYP17A1, which participates in both cortisol and androgen synthesis.
ANSWER: E
Rationale:
Ketoconazole inhibits multiple cytochrome P450 (CYP) enzymes within the adrenal cortex, principally CYP11A1 (cholesterol side-chain cleavage enzyme), CYP11B1 (11-beta-hydroxylase), and CYP17A1 (17-alpha-hydroxylase/17,20-lyase). Of these, the most potent inhibitory effect is at CYP17A1, which participates in both cortisol synthesis (through its 17-alpha-hydroxylase activity producing 17-OH-progesterone) and androgen synthesis (through its 17,20-lyase activity). This multi-enzyme inhibition is what makes ketoconazole effective at reducing UFC in 50 to 60% of Cushing disease patients at doses of 400 to 1,200 mg daily. Because CYP17A1 also governs androgen synthesis, ketoconazole produces a degree of androgen suppression as a pharmacodynamic consequence.
Option A is incorrect because CYP11B2 (aldosterone synthase) inhibition is associated with osilodrostat and metyrapone to some degree, but it is not ketoconazole's primary target or the basis of its cortisol-lowering effect; ketoconazole's multi-enzyme CYP inhibition acts primarily through CYP17A1 and upstream enzymes.
Option B is incorrect because while CYP11B1 is one of the enzymes inhibited by ketoconazole, it is not the most potent target; CYP17A1 inhibition is more potent, and metyrapone is the drug specifically characterized by selective CYP11B1 inhibition.
Option C is incorrect because 3-beta-hydroxysteroid dehydrogenase (3β-HSD) is not a cytochrome P450 enzyme and is not a significant target of ketoconazole; ketoconazole's specificity is for imidazole-sensitive CYP enzymes, not the dehydrogenase family.
Option D is incorrect because while ketoconazole does inhibit CYP11A1, it is not the primary mechanism for its cortisol-lowering effect at clinical doses; CYP17A1 is the most potent target, and framing CYP11A1 as the primary mechanism mischaracterizes the pharmacology of ketoconazole in Cushing disease.
11.A 50-year-old man with renal transplant and Cushing disease on tacrolimus-based immunosuppression is started on ketoconazole 400 mg twice daily for cortisol control. Within 2 weeks, his tacrolimus trough level rises from 7 ng/mL to 22 ng/mL, and he develops signs of tacrolimus toxicity including tremor and rising creatinine. Which of the following best explains the mechanism of this drug interaction?
A)Ketoconazole induces CYP3A4 in the small intestinal wall and liver, increasing tacrolimus first-pass metabolism and paradoxically raising systemic tacrolimus exposure through a compensatory increase in intestinal absorption rate.
B)Ketoconazole is a strong inhibitor of CYP3A4 (cytochrome P450 3A4), the primary enzyme responsible for tacrolimus metabolism; CYP3A4 inhibition markedly reduces tacrolimus clearance and dramatically increases tacrolimus plasma concentrations, producing toxicity at previously well-tolerated doses.
C)Ketoconazole displaces tacrolimus from plasma protein binding sites, increasing the free (unbound) fraction of tacrolimus and producing toxicity through enhanced drug distribution to target organs without changing total tacrolimus clearance.
D)Ketoconazole inhibits the multidrug resistance protein 1 (MDR1) transporter (P-glycoprotein) at the renal tubule, reducing tacrolimus renal excretion and causing drug accumulation through a transport-based rather than metabolic mechanism.
E)Ketoconazole competes with tacrolimus for FK-binding protein 12 (FKBP12), the intracellular binding protein through which tacrolimus exerts its immunosuppressive effect, increasing unbound tacrolimus concentration and amplifying calcineurin inhibition.
ANSWER: B
Rationale:
Ketoconazole is a strong inhibitor of CYP3A4, the cytochrome P450 isoform responsible for the majority of tacrolimus first-pass and systemic metabolism. By blocking CYP3A4-mediated tacrolimus clearance, ketoconazole dramatically increases tacrolimus plasma concentrations — this interaction is well documented and clinically serious, as the narrow therapeutic index of tacrolimus means even modest concentration increases produce nephrotoxicity, neurotoxicity (tremor, headache), and increased infection risk. The same CYP3A4 inhibition mechanism underlies ketoconazole's interactions with cyclosporine, statins, calcium channel blockers, and many other CYP3A4 substrates. Ketoconazole also inhibits P-glycoprotein, which contributes to increased intestinal absorption of tacrolimus, amplifying the effect beyond pure metabolic inhibition. Management requires tacrolimus dose reduction (often 50% or more) and frequent trough monitoring when this combination cannot be avoided; ideally, alternative cortisol-lowering agents should be considered in transplant patients on calcineurin inhibitors.
Option A is incorrect because ketoconazole inhibits rather than induces CYP3A4; CYP3A4 induction would reduce tacrolimus exposure, not increase it, and is the mechanism of drugs such as rifampin and mitotane.
Option C is incorrect because tacrolimus is extensively bound to erythrocytes and plasma proteins, but protein displacement interactions typically produce transient and modest effects on free drug — the magnitude of the tacrolimus elevation in this case is far more consistent with metabolic inhibition than protein displacement.
Option D is incorrect because while P-glycoprotein (MDR1) inhibition by ketoconazole does contribute to the interaction by increasing intestinal absorption, the primary mechanism driving the large trough elevation is CYP3A4 metabolic inhibition rather than renal transporter blockade; furthermore, tacrolimus is not substantially eliminated unchanged by the kidney.
Option E is incorrect because FKBP12 competition is not a recognized mechanism of ketoconazole drug interaction; FKBP12 is an intracellular binding protein, and ketoconazole does not bind FKBP12 or alter tacrolimus-FKBP12 complex formation.
12.A 39-year-old woman with Cushing disease and persistent hypercortisolism after two pituitary surgeries is started on metyrapone 750 mg three times daily. The prescribing team orders serum 11-deoxycortisol levels to assess pharmacological effect. Which of the following best explains the relationship between metyrapone's enzyme target and the rationale for measuring 11-deoxycortisol?
A)Metyrapone inhibits CYP17A1 (17-alpha-hydroxylase), blocking the conversion of 17-OH-pregnenolone to dehydroepiandrosterone (DHEA); 11-deoxycortisol accumulates as the immediate upstream substrate of CYP17A1 and serves as a direct marker of enzyme inhibition.
B)Metyrapone inhibits CYP11A1 (cholesterol side-chain cleavage enzyme), preventing cholesterol from entering the steroidogenic pathway; 11-deoxycortisol accumulates because the entire pathway backs up from the point of blockade.
C)Metyrapone inhibits CYP11B2 (aldosterone synthase) as its primary target; 11-deoxycortisol accumulates because blockade of aldosterone synthesis diverts steroid precursors toward the glucocorticoid pathway.
D)Metyrapone selectively inhibits CYP11B1 (11-beta-hydroxylase), the enzyme that catalyzes the final step in cortisol synthesis — conversion of 11-deoxycortisol to cortisol. Because this step is blocked, 11-deoxycortisol accumulates in plasma and is measured as a surrogate marker of metyrapone's pharmacodynamic effect while cortisol falls.
E)Metyrapone inhibits CYP21A2 (21-hydroxylase), which converts 17-OH-progesterone to 11-deoxycortisol; paradoxically, blockade of the enzyme producing 11-deoxycortisol leads to its accumulation through a compensatory ACTH surge that drives excess substrate through the residual uninhibited enzyme.
ANSWER: D
Rationale:
Metyrapone is a selective inhibitor of CYP11B1 (11-beta-hydroxylase), which catalyzes the final step in cortisol synthesis within the zona fasciculata — the conversion of 11-deoxycortisol to cortisol. By blocking this terminal enzymatic step, metyrapone prevents cortisol synthesis, and the immediate upstream substrate, 11-deoxycortisol, accumulates in plasma. Measurement of plasma 11-deoxycortisol serves as a direct, sensitive pharmacodynamic marker of CYP11B1 inhibition: rising 11-deoxycortisol confirms adequate drug effect, while failure of 11-deoxycortisol to rise suggests insufficient dosing or poor adherence. Cortisol levels fall as the blocked pathway limits downstream synthesis. This CYP11B1 selectivity distinguishes metyrapone pharmacologically from ketoconazole (which inhibits multiple adrenal CYP enzymes) and osilodrostat (which inhibits both CYP11B1 and CYP11B2).
Option A is incorrect because metyrapone's target is CYP11B1, not CYP17A1; CYP17A1 is the enzyme most potently inhibited by ketoconazole, and 11-deoxycortisol is not the direct upstream substrate of CYP17A1 — rather, it is the immediate substrate of CYP11B1.
Option B is incorrect because metyrapone does not inhibit CYP11A1 (the cholesterol side-chain cleavage enzyme responsible for the first committed step of steroidogenesis); that enzyme is one of the targets of ketoconazole and mitotane, not metyrapone.
Option C is incorrect because CYP11B2 (aldosterone synthase) inhibition is a characteristic of osilodrostat rather than metyrapone; metyrapone's primary target is CYP11B1, and while the CYP11B2 pathway is adjacent in the adrenal cortex, metyrapone does not selectively block aldosterone synthase.
Option E is incorrect because metyrapone does not inhibit CYP21A2 (21-hydroxylase), which is the enzyme that produces 11-deoxycortisol from 17-OH-progesterone; CYP21A2 blockade is the mechanism of congenital adrenal hyperplasia pathophysiology, not metyrapone action.
13.A 45-year-old woman on metyrapone for Cushing disease develops worsening hypertension and hypokalemia after 6 weeks of therapy, despite falling urinary free cortisol (UFC) levels confirming an adequate pharmacological response. Which of the following best explains the mechanism responsible for these new cardiovascular and electrolyte abnormalities?
A)Metyrapone's block of CYP11B1 (11-beta-hydroxylase) prevents conversion of 11-deoxycorticosterone (DOC) to corticosterone, causing DOC to accumulate; DOC is a weak mineralocorticoid that, when present in excess, activates mineralocorticoid receptors in the renal tubule, promoting sodium retention and potassium excretion and producing hypertension and hypokalemia.
B)Metyrapone inhibits CYP11B2 (aldosterone synthase) as a secondary action, reducing aldosterone synthesis and triggering a compensatory renin-angiotensin system activation that paradoxically raises blood pressure through angiotensin II-mediated vasoconstriction.
C)levels confirming an adequate pharmacological response. Which of the following best explains the mechanism responsible for these new cardiovascular and electrolyte abnormalities? A) Metyrapone's block of CYP11B1 (11-beta-hydroxylase) prevents conversion of 11-deoxycorticosterone (DOC) to corticosterone, causing DOC to accumulate; DOC is a weak mineralocorticoid that, when present in excess, activates mineralocorticoid receptors in the renal tubule, promoting sodium retention and potassium excretion and producing hypertension and hypokalemia. B) Metyrapone inhibits CYP11B2 (aldosterone synthase) as a secondary action, reducing aldosterone synthesis and triggering a compensatory renin-angiotensin system activation that paradoxically raises blood pressure through angiotensin II-mediated vasoconstriction. C) The hypertension and hypokalemia result from metyrapone's direct inhibition of the vascular endothelial 11-beta-hydroxysteroid dehydrogenase type 2 (11β-HSD2) enzyme, which normally inactivates cortisol in vascular tissue; cortisol accumulation in vascular walls then activates mineralocorticoid receptors directly.
D)Metyrapone increases ACTH secretion through reduced cortisol feedback, and the excess ACTH drives overproduction of adrenal androgens; these androgens are converted peripherally to mineralocorticoid-active steroids by adipose tissue aromatase, producing secondary hyperaldosteronism-like physiology.
E)The hypertension and hypokalemia indicate adrenal insufficiency from excessive CYP11B1 inhibition, causing a shift to catecholamine-dependent blood pressure maintenance; the catecholamine surge produces hypertension while simultaneously activating beta-2-adrenergic receptors that promote renal potassium wasting.
ANSWER: A
Rationale:
Metyrapone's block of CYP11B1 (11-beta-hydroxylase) prevents the conversion of both 11-deoxycortisol to cortisol and 11-deoxycorticosterone (DOC) to corticosterone. Because the CYP11B1 block is proximal to CYP11B2 (aldosterone synthase) in the mineralocorticoid synthesis pathway, DOC accumulates in the zona glomerulosa as well as the zona fasciculata. DOC is a weak mineralocorticoid that, when present in excess driven by ongoing ACTH stimulation (which rises as cortisol feedback falls), activates mineralocorticoid receptors in the renal collecting duct — promoting sodium and water retention and increasing potassium excretion. This results in hypertension and hypokalemia that can emerge or worsen as metyrapone doses increase and cortisol falls effectively. Metyrapone does not significantly inhibit androgen synthesis, and the accumulating 11-deoxycortisol itself is not androgenic.
Option B is incorrect because metyrapone does not primarily inhibit CYP11B2 (aldosterone synthase); that is a defining pharmacological property of osilodrostat. Metyrapone's block is proximal to CYP11B2, and the mineralocorticoid excess physiology is driven by DOC accumulation, not by aldosterone deficiency and RAS activation.
Option C is incorrect because metyrapone does not inhibit 11-beta-hydroxysteroid dehydrogenase type 2 (11β-HSD2); that enzyme inactivates cortisol to cortisone in mineralocorticoid target tissues and is not a target of metyrapone. Apparent mineralocorticoid excess syndrome from 11β-HSD2 deficiency or inhibition (by licorice-derived glycyrrhizin) is a distinct pathological mechanism.
Option D is incorrect because while ACTH does rise with effective metyrapone therapy, the resulting adrenal steroid accumulation that causes mineralocorticoid effects is DOC specifically — not adrenal androgens converted peripherally to mineralocorticoid-active steroids; that proposed pathway is not the established mechanism.
Option E is incorrect because the clinical scenario describes an effective pharmacological response (falling UFC) alongside hypertension and hypokalemia, which is the characteristic pattern of DOC-driven mineralocorticoid excess — not adrenal insufficiency; adrenal insufficiency would produce hypotension and hyponatremia, the opposite of what is described.
14.A 48-year-old man with refractory Cushing disease is being switched from metyrapone to osilodrostat (Isturisa) due to progressive hypertension and hypokalemia on metyrapone. His endocrinologist notes that osilodrostat has an additional enzyme-inhibitory activity beyond CYP11B1 blockade that distinguishes its adverse effect profile from metyrapone. Which of the following best describes this distinguishing pharmacological property and its clinical implication?
A)Unlike metyrapone, osilodrostat also inhibits CYP17A1 (17-alpha-hydroxylase), reducing adrenal androgen synthesis in addition to cortisol; the clinical implication is hirsutism improvement in women but potential sexual dysfunction in men from androgen deficiency.
B)Unlike metyrapone, osilodrostat also inhibits CYP11A1 (cholesterol side-chain cleavage enzyme), blocking the first committed step in steroidogenesis; the clinical implication is a more complete suppression of all steroid classes including aldosterone, cortisol, and androgens simultaneously.
C)Unlike metyrapone, osilodrostat also inhibits CYP11B2 (aldosterone synthase), reducing aldosterone synthesis in addition to cortisol; rather than the DOC-driven mineralocorticoid excess seen with metyrapone, osilodrostat can cause hypotension and hypokalemia through aldosterone deficiency, and electrolyte and blood pressure monitoring is required at each dose titration.
D)Unlike metyrapone, osilodrostat also inhibits CYP19A1 (aromatase), reducing estrogen synthesis from androgen precursors; the clinical implication is hypoestrogenemia and bone density loss in premenopausal women requiring estrogen supplementation during therapy.
E)Unlike metyrapone, osilodrostat also inhibits hepatic CYP3A4, producing extensive drug-drug interactions with immunosuppressants, statins, and azole antifungals that must be assessed before initiation.
ANSWER: C
Rationale:
Osilodrostat is a potent oral CYP11B1 (11-beta-hydroxylase) inhibitor with the additional pharmacological property of inhibiting CYP11B2 (aldosterone synthase), which catalyzes the final steps in aldosterone synthesis. This dual enzyme inhibition profile distinguishes osilodrostat from metyrapone, which selectively inhibits CYP11B1 without significant CYP11B2 inhibition. The clinical consequence is that osilodrostat reduces aldosterone production in addition to cortisol, creating a risk of hypotension and hypokalemia through aldosterone deficiency — the opposite mineralocorticoid mechanism from metyrapone (which causes mineralocorticoid excess via DOC accumulation). Potassium and sodium levels, as well as blood pressure, must be monitored at each dose titration of osilodrostat. Phase 3 trials reported UFC normalization in approximately 53 to 79% of patients at 12 weeks, with a favorable efficacy profile. Osilodrostat is also a moderate inhibitor of CYP2D6 (cytochrome P450 2D6) and a substrate of CYP3A4, but these are secondary properties; the primary pharmacological distinction from metyrapone is the CYP11B2 inhibitory activity.
Option A is incorrect because osilodrostat does not significantly inhibit CYP17A1; that enzyme is a primary target of ketoconazole, and CYP17A1 inhibition with resulting androgen suppression is not a distinguishing feature of osilodrostat versus metyrapone.
Option B is incorrect because osilodrostat does not inhibit CYP11A1 (P450scc); complete suppression of all steroid synthesis from the first step is the mechanism of agents like mitotane, not osilodrostat.
Option D is incorrect because osilodrostat does not inhibit CYP19A1 (aromatase); aromatase inhibition is the mechanism of anastrozole and letrozole used in breast cancer management, and it is not a property of this drug class.
Option E is incorrect because it is CYP2D6 inhibition (moderate) and CYP3A4 substrate activity that characterize osilodrostat's drug interaction profile; hepatic CYP3A4 inhibition — the mechanism underlying ketoconazole's extensive drug interactions — is not a property of osilodrostat.
15.A 52-year-old woman with Cushing disease is started on osilodrostat. Her current medications include amitriptyline 75 mg nightly for depression and metoprolol succinate 50 mg daily for hypertension. Two weeks after starting osilodrostat, she reports worsening dry mouth, urinary hesitancy, and an episode of symptomatic bradycardia. Which of the following best explains the mechanism responsible for these new symptoms?
A)Osilodrostat inhibits CYP3A4 (cytochrome P450 3A4), reducing the hepatic clearance of both amitriptyline and metoprolol; because both drugs are primarily metabolized by CYP3A4, plasma concentrations of both agents rise and produce tricyclic antidepressant (TCA) anticholinergic toxicity and beta-blocker-mediated bradycardia simultaneously.
B)Osilodrostat induces CYP2D6 (cytochrome P450 2D6), accelerating the metabolism of amitriptyline and metoprolol to toxic active metabolites; nortriptyline accumulation from amitriptyline demethylation produces anticholinergic effects, and alpha-hydroxy-metoprolol excess produces enhanced cardiac conduction slowing.
C)Osilodrostat activates mineralocorticoid receptors as an off-target effect, causing sodium and water retention that raises blood pressure and necessitates increased metoprolol dosing; the higher metoprolol doses produce bradycardia while adrenergic stimulation from fluid retention worsens TCA anticholinergic symptoms.
D)Osilodrostat reduces cortisol, which normally inhibits CYP2D6 expression; as cortisol falls, CYP2D6 activity increases transiently, converting amitriptyline more rapidly to nortriptyline and generating excess anticholinergic effects from nortriptyline accumulation.
E)Osilodrostat is a moderate inhibitor of CYP2D6 (cytochrome P450 2D6), the enzyme responsible for amitriptyline hydroxylation and the primary route of metoprolol O-demethylation; CYP2D6 inhibition increases plasma concentrations of both drugs, producing enhanced anticholinergic toxicity from elevated amitriptyline and tricyclic metabolite levels, and enhanced beta-blockade with bradycardia from elevated metoprolol concentrations.
ANSWER: E
Rationale:
Osilodrostat is a moderate inhibitor of CYP2D6 (cytochrome P450 2D6). This is clinically significant because CYP2D6 is responsible for the oxidative metabolism of numerous drugs with narrow therapeutic indices, including tricyclic antidepressants (TCAs) such as amitriptyline — whose hydroxylation to active metabolites and subsequent inactivation is CYP2D6-dependent — and metoprolol, whose O-demethylation is the primary clearance pathway. CYP2D6 inhibition by osilodrostat reduces the clearance of both amitriptyline and metoprolol, increasing plasma concentrations of each and producing enhanced pharmacodynamic effects: elevated amitriptyline and its active metabolite nortriptyline cause intensified anticholinergic toxicity (dry mouth, urinary hesitancy, constipation), while elevated metoprolol produces enhanced beta-blockade including symptomatic bradycardia. The osilodrostat prescribing information specifically flags CYP2D6-sensitive drugs such as TCAs and certain beta-blockers as requiring monitoring or dose adjustment when osilodrostat is initiated.
Option A is incorrect because osilodrostat is a substrate of CYP3A4 (not a CYP3A4 inhibitor); both amitriptyline and metoprolol are predominantly metabolized by CYP2D6, not CYP3A4, making CYP3A4 inhibition the wrong enzyme and the wrong direction of effect.
Option B is incorrect because osilodrostat is an inhibitor of CYP2D6, not an inducer; induction would accelerate metabolism and lower drug levels, producing the opposite of the described toxicity.
Option C is incorrect because osilodrostat reduces aldosterone synthesis through CYP11B2 inhibition, which tends to cause hypotension and aldosterone deficiency — not mineralocorticoid receptor activation or fluid retention.
Option D is incorrect because there is no established mechanism by which falling cortisol levels transiently upregulate CYP2D6 activity; the clinical interaction is a direct pharmacokinetic one caused by osilodrostat's CYP2D6 inhibitory property, not an indirect endocrine-metabolic effect.
16.A 58-year-old man on long-term warfarin anticoagulation for atrial fibrillation is started on mitotane for adrenocortical carcinoma (ACC). Within 3 weeks, his international normalized ratio (INR) drops from a therapeutic 2.5 to 1.2 despite no changes to his warfarin dose. Which of the following best explains this change in anticoagulation status?
A)Mitotane is a substrate of CYP2C9, the enzyme responsible for warfarin S-enantiomer metabolism; competition for CYP2C9 binding reduces warfarin clearance and paradoxically lowers the INR by shifting warfarin toward the less potent R-enantiomer.
B)Mitotane is a potent inducer of both CYP3A4 (cytochrome P450 3A4) and CYP2B6 (cytochrome P450 2B6), and also induces CYP2C9, substantially accelerating warfarin metabolism and reducing warfarin plasma concentrations; the resulting sub-therapeutic anticoagulation requires warfarin dose increases of 50% or more, with INR checks every 2 weeks until a new stable dose is achieved.
C). Within 3 weeks, his international normalized ratio (INR) drops from a therapeutic 2.5 to 1.2 despite no changes to his warfarin dose. Which of the following best explains this change in anticoagulation status? A) Mitotane is a substrate of CYP2C9, the enzyme responsible for warfarin S-enantiomer metabolism; competition for CYP2C9 binding reduces warfarin clearance and paradoxically lowers the INR by shifting warfarin toward the less potent R-enantiomer. B) Mitotane is a potent inducer of both CYP3A4 (cytochrome P450 3A4) and CYP2B6 (cytochrome P450 2B6), and also induces CYP2C9, substantially accelerating warfarin metabolism and reducing warfarin plasma concentrations; the resulting sub-therapeutic anticoagulation requires warfarin dose increases of 50% or more, with INR checks every 2 weeks until a new stable dose is achieved. C) Mitotane increases adrenal production of vitamin K-dependent clotting factor precursors by stimulating adrenocortical reserve through compensatory ACTH stimulation, producing a hypercoagulable state that functionally opposes warfarin's anticoagulant effect without changing warfarin concentrations.
D)Mitotane is absorbed predominantly in adipose tissue due to its high lipid solubility, and it displaces warfarin from adipose storage depots into the systemic circulation; the resulting redistribution transiently increases warfarin volume of distribution and lowers free warfarin plasma concentrations.
E)Mitotane inhibits vitamin K epoxide reductase (VKOR) through an adrenolytic mechanism unrelated to its enzyme-inducing properties, partially reversing warfarin's anticoagulant effect at the coagulation cascade level.
ANSWER: B
Rationale:
Mitotane is a potent inducer of multiple cytochrome P450 enzymes, most importantly CYP3A4, CYP2B6, and CYP2C9. Warfarin undergoes extensive hepatic metabolism — the pharmacologically active S-enantiomer is primarily metabolized by CYP2C9, and the R-enantiomer by CYP3A4 and CYP1A2. Mitotane's induction of CYP2C9 and CYP3A4 substantially accelerates warfarin clearance, lowering warfarin plasma concentrations and reducing its anticoagulant effect; INR can fall to sub-therapeutic levels quickly after mitotane initiation. The clinical consequence is serious: patients with ACC already carry elevated thromboembolism risk from the cortisol-driven hypercoagulable state, and inadequate anticoagulation compounds this risk. Management requires warfarin dose increases — often 50% or more — and frequent INR monitoring (every 2 weeks) until a new stable therapeutic INR is achieved. The same CYP induction mechanism also accelerates metabolism of corticosteroids (requiring higher replacement doses) and oral contraceptives (reducing efficacy).
Option A is incorrect because mitotane is an enzyme inducer, not a CYP2C9 substrate competitor; competition for CYP2C9 binding would inhibit warfarin metabolism and raise the INR — the opposite of what is observed; furthermore, R/S enantiomer shifts from enzyme competition do not produce clinically significant INR changes through the mechanism described.
Option C is incorrect because mitotane produces adrenal cortical destruction rather than stimulation; ACTH rises compensatorily, but adrenal output falls, and there is no mechanism by which mitotane-driven ACTH stimulation increases vitamin K-dependent clotting factor synthesis to a degree sufficient to explain a clinically significant INR fall.
Option D is incorrect because mitotane's lipophilicity drives its accumulation in adipose tissue and contributes to its slow onset and long duration of action, but it does not displace warfarin from adipose storage; warfarin is not stored in adipose tissue to a clinically significant degree, and displacement pharmacokinetics are not the mechanism of this interaction.
Option E is incorrect because mitotane does not inhibit vitamin K epoxide reductase (VKOR) — that is warfarin's own mechanism of action; mitotane's effect on warfarin is entirely through enzyme induction reducing warfarin concentrations, not through VKOR inhibition.
17.A 61-year-old man is started on mitotane for locally advanced adrenocortical carcinoma. The treating oncologist counsels him that all patients on maintenance mitotane require a specific hormonal supplementation regimen for as long as they remain on the drug. Which of the following best explains the pharmacological basis for this requirement and the specific replacement that is needed?
A)Mitotane inhibits pituitary ACTH secretion through a central nervous system (CNS) toxic effect; the resulting secondary adrenal insufficiency requires glucocorticoid replacement only, as mineralocorticoid secretion is preserved through the renin-angiotensin-aldosterone system independent of ACTH.
B)Mitotane induces CYP3A4 in the adrenal cortex, accelerating the catabolism of endogenous cortisol and aldosterone; replacement with physiological doses of both glucocorticoid and mineralocorticoid is required to compensate for increased steroid clearance, not for actual adrenal destruction.
C)Mitotane blocks corticotropin-releasing hormone (CRH) receptors in the hypothalamus, reducing ACTH drive and causing functional adrenal atrophy; both glucocorticoid and mineralocorticoid replacement are required, but adrenal tissue recovers after drug discontinuation because the mechanism is functional suppression, not structural destruction.
D)Mitotane produces selective cytotoxic destruction of adrenocortical cells through the formation of reactive acyl chloride intermediates that alkylate adrenocortical cell proteins, resulting in progressive adrenocortical destruction; because both glucocorticoid and mineralocorticoid-producing zones are destroyed, all patients on maintenance mitotane require lifelong glucocorticoid and mineralocorticoid replacement therapy.
E)Mitotane inhibits only the zona fasciculata, producing glucocorticoid deficiency requiring cortisol replacement; the zona glomerulosa and its mineralocorticoid function are pharmacologically spared by mitotane's selective cytotoxic mechanism, so fludrocortisone is not required.
ANSWER: D
Rationale:
Mitotane (o,p'-DDD) is an adrenolytic agent derived from the insecticide DDT that produces progressive destruction of the adrenal cortex. Its cytotoxic mechanism involves the formation of reactive acyl chloride intermediates that alkylate adrenocortical cell proteins, producing selective adrenal cell death. In addition to this direct cytotoxic effect, mitotane inhibits multiple adrenal steroidogenic enzymes including CYP11A1, CYP11B1, CYP11B2, and CYP17A1. The combination of structural adrenocortical destruction and enzyme inhibition results in progressive loss of both glucocorticoid and mineralocorticoid production from all functional zones of the adrenal cortex. Because both the zona fasciculata (cortisol) and zona glomerulosa (aldosterone) are affected, all patients on maintenance mitotane require both glucocorticoid replacement (hydrocortisone or equivalent) and mineralocorticoid replacement (fludrocortisone) for the duration of therapy — typically lifelong in the context of ACC management. Doses of replacement steroids often need to be higher than standard because mitotane's potent CYP3A4 and CYP2B6 induction accelerates corticosteroid catabolism.
Option A is incorrect because mitotane's adrenal insufficiency is caused by direct adrenocortical destruction, not by pituitary ACTH suppression; ACTH levels actually rise as cortisol falls; and mineralocorticoid replacement is required because the zona glomerulosa is also destroyed — it is not preserved through the renin-angiotensin system when adrenal tissue is absent.
Option B is incorrect because CYP3A4 induction does accelerate corticosteroid metabolism (requiring higher replacement doses), but the primary reason for mandatory hormone replacement is adrenocortical destruction, not merely enhanced corticosteroid clearance; the distinction matters because destruction means endogenous production is permanently lost.
Option C is incorrect because mitotane does not block CRH receptors in the hypothalamus; it acts directly on adrenocortical cells through cytotoxic and enzyme-inhibitory mechanisms, and the resulting adrenal insufficiency is structural (from cell death), not functional suppression — recovery after drug discontinuation is not reliably expected.
Option E is incorrect because mitotane's cytotoxic effect involves destruction of all adrenocortical zones, including the zona glomerulosa; aldosterone deficiency and the need for mineralocorticoid replacement are well-established consequences of mitotane therapy and are not pharmacologically spared.
18.A 60-year-old woman with Cushing syndrome of pituitary origin who is not a surgical candidate has worsening hyperglycemia requiring increasing insulin doses. Her physician considers adding mifepristone (Korlym). Which of the following correctly identifies mifepristone's FDA-approved indication and mechanism of action in this clinical context?
A)Mifepristone is approved for the management of hyperglycemia in adults with Cushing syndrome who have failed surgery or are not surgical candidates; it acts as a glucocorticoid receptor (GR) antagonist that blocks cortisol signaling at target tissues, improving glucose metabolism without reducing cortisol secretion.
B)Mifepristone is approved as primary medical therapy for Cushing disease to normalize urinary free cortisol (UFC) before surgical evaluation; it acts by reducing ACTH secretion from the corticotroph adenoma through glucocorticoid receptor-mediated negative feedback restoration.
C)before surgical evaluation; it acts by reducing ACTH secretion from the corticotroph adenoma through glucocorticoid receptor-mediated negative feedback restoration. C) Mifepristone is approved for Cushing syndrome only when the etiology is adrenal carcinoma; for pituitary-origin Cushing syndrome, its use is off-label because the drug has not been studied in corticotroph adenoma patients.
D)Mifepristone is approved for Cushing syndrome and acts by inhibiting CYP11B1 (11-beta-hydroxylase) in the adrenal cortex; its glucocorticoid receptor antagonism is an off-target effect that contributes to symptom relief but is not the FDA-approved mechanism.
E)Mifepristone is approved for Cushing syndrome and functions as both a glucocorticoid receptor antagonist and a steroidogenesis inhibitor; its dual mechanism allows it to lower cortisol levels while simultaneously blocking peripheral glucocorticoid signaling, producing synergistic metabolic benefit.
ANSWER: A
Rationale:
Mifepristone (Korlym) is a synthetic GR antagonist approved by the FDA for the management of hyperglycemia secondary to Cushing syndrome in adults with endogenous Cushing syndrome — including Cushing disease — who have failed surgery or are not surgical candidates. The approved indication is specifically for hyperglycemia control, not for the broader management of hypercortisolism itself; this distinction is important because mifepristone does not reduce cortisol secretion and UFC levels rise during therapy. The mechanism of action is competitive antagonism at the glucocorticoid receptor (GR) at target tissues, particularly skeletal muscle and liver, which restores insulin sensitivity and glucose metabolism despite ongoing cortisol excess. Mifepristone binds GR with approximately three times the affinity of cortisol. Because GR blockade eliminates negative feedback on the hypothalamic-pituitary axis, ACTH and cortisol levels rise during therapy — a predictable pharmacodynamic response that does not indicate treatment failure.
Option B is incorrect because mifepristone does not restore negative feedback or reduce ACTH secretion; on the contrary, ACTH rises during mifepristone therapy because GR blockade prevents cortisol from suppressing pituitary ACTH release; the drug is not approved as a tool to reduce UFC, and using it pre-operatively to reduce cortisol is not its mechanism.
Option C is incorrect because mifepristone's FDA approval encompasses Cushing syndrome of all etiologies, not exclusively adrenal carcinoma; it has been studied in pituitary Cushing disease patients in the pivotal SEISMIC trial, where hyperglycemia and clinical improvements were documented.
Option D is incorrect because mifepristone does not inhibit CYP11B1 or any other adrenal steroidogenic enzyme; its mechanism is entirely receptor-mediated GR antagonism at target tissues, and it produces no cortisol biosynthesis inhibition.
Option E is incorrect because mifepristone does not inhibit steroidogenesis; as a GR antagonist, it reduces glucocorticoid signaling at receptor level while cortisol secretion actually increases, so it has no steroidogenesis inhibitory component and does not lower cortisol levels.
19.A 44-year-old woman underwent bilateral adrenalectomy (BLA) for refractory Cushing disease 3 years ago and was doing well on glucocorticoid and mineralocorticoid replacement. She now presents with progressive headache, new bitemporal visual field deficits, deepening skin hyperpigmentation, and a serum adrenocorticotropic hormone (ACTH) level of 680 pg/mL. Pituitary MRI shows a 24 mm invasive sellar mass with cavernous sinus involvement. Which of the following best describes the pathophysiological mechanism responsible for this clinical presentation?
A)for refractory Cushing disease 3 years ago and was doing well on glucocorticoid and mineralocorticoid replacement. She now presents with progressive headache, new bitemporal visual field deficits, deepening skin hyperpigmentation, and a serum adrenocorticotropic hormone (ACTH) level of 680 pg/mL. Pituitary MRI shows a 24 mm invasive sellar mass with cavernous sinus involvement. Which of the following best describes the pathophysiological mechanism responsible for this clinical presentation? A) This presentation reflects recurrence of the original Cushing disease, with regrowth of the corticotroph adenoma driven by loss of surgical suppression; the high ACTH level indicates active corticosteroid hypersecretion, but the patient cannot develop cortisol excess because her adrenal glands have been removed.
B)This presentation is consistent with a secondary pituitary adenoma that developed de novo following BLA, driven by an ACTH-independent mechanism involving loss of adrenal-derived angiogenesis factors that normally suppress pituitary tumor neovascularization.
C)Following bilateral adrenalectomy, cortisol production ceases and hypothalamic-pituitary negative feedback is permanently lost; without cortisol feedback suppressing ACTH release, the residual corticotroph adenoma undergoes unopposed, sustained ACTH hypersecretion and rapid tumor growth — this is Nelson syndrome, characterized by an aggressive, invasive ACTH-secreting adenoma, extremely high ACTH levels, and hyperpigmentation from ACTH-driven melanocyte-stimulating hormone (MSH) activity.
D)The elevated ACTH and pituitary mass represent a parasellar meningioma that has developed as a late complication of adrenalectomy-related hormonal imbalance; meningiomas express ACTH receptors that are stimulated by the chronically elevated ACTH, causing tumor growth and paraneoplastic ACTH secretion.
E)Following BLA, the absence of cortisol feedback triggers compensatory hypothalamic corticotropin-releasing hormone (CRH) hypersecretion, which directly stimulates pituitary lactotroph cells; the visual field deficit and high ACTH reflect a mixed CRH-secreting/lactotroph tumor rather than a pure corticotroph adenoma.
ANSWER: C
Rationale:
Nelson syndrome is the development of an aggressive, invasive ACTH-secreting corticotroph adenoma following bilateral adrenalectomy performed for refractory Cushing disease. The pathophysiology is straightforward: when both adrenal glands are removed, cortisol production ceases entirely, and the normal hypothalamic-pituitary negative feedback loop that normally restrains ACTH secretion and limits corticotroph tumor growth is permanently disrupted. Without cortisol suppression, the residual pituitary corticotroph adenoma undergoes rapid, unopposed ACTH hypersecretion and accelerated tumor growth, often becoming invasive and involving adjacent structures such as the cavernous sinus. ACTH levels are characteristically extremely high — often above 500 pg/mL and sometimes several thousand pg/mL. The striking skin hyperpigmentation is a clinical hallmark driven by ACTH's structural homology with melanocyte-stimulating hormone (MSH); both ACTH and alpha-MSH are derived from the proopiomelanocortin (POMC) precursor, and excess ACTH activates melanocortin receptors in skin melanocytes. Pituitary radiotherapy administered after BLA can reduce but does not eliminate the risk of Nelson syndrome. Treatment options include transsphenoidal surgery, radiotherapy, and medical therapy including pasireotide and cabergoline.
Option A is incorrect because the presentation does not represent simple recurrence of the original Cushing disease; Nelson syndrome is a distinct entity defined by post-adrenalectomy corticotroph adenoma growth and very high ACTH, and the adrenalectomy itself drives the syndrome by removing negative feedback rather than representing a failure of the original treatment.
Option B is incorrect because Nelson syndrome is not a de novo tumor driven by loss of adrenal-derived angiogenesis factors; it represents growth of the existing corticotroph adenoma driven by the specific loss of cortisol-mediated negative feedback on the pituitary-hypothalamic axis.
Option D is incorrect because the mass is a corticotroph adenoma, not a meningioma; there is no recognized syndrome of ACTH-receptor-bearing meningiomas developing after adrenalectomy, and paraneoplastic ACTH secretion from meningiomas is not a described clinical entity.
Option E is incorrect because Nelson syndrome involves corticotroph (not lactotroph) adenoma growth; the elevated ACTH is produced by the corticotroph adenoma, not by CRH hypersecretion stimulating lactotroph cells; and mixed CRH/lactotroph tumors are not a recognized consequence of bilateral adrenalectomy.
20.A 49-year-old woman with Cushing disease is started on pasireotide SC 600 mcg twice daily. She has no prior history of diabetes mellitus. At her 6-week follow-up visit, her fasting glucose is 198 mg/dL and her HbA1c has risen to 8.1%. Pasireotide is providing meaningful UFC reduction and the team wishes to continue it. Which of the following agents is most appropriate for first-line management of pasireotide-induced hyperglycemia in this setting?
A)Initiate metformin at standard starting doses; metformin is preferred because pasireotide-induced hyperglycemia results primarily from increased hepatic glucose output through AMPK (AMP-activated protein kinase) suppression, which metformin directly reverses.
B)Initiate a sulfonylurea such as glipizide; pasireotide-induced hyperglycemia is driven by relative insulin deficiency from beta-cell suppression, and sulfonylureas are preferred because they stimulate insulin secretion through a mechanism independent of the somatostatin receptor-mediated beta-cell inhibition.
C)Initiate a sodium-glucose cotransporter 2 (SGLT2) inhibitor; SGLT2 inhibitors are preferred for pasireotide-induced hyperglycemia because they lower glucose through an insulin-independent renal mechanism, bypassing the impaired glucose-stimulated insulin secretion caused by pasireotide.
D)Initiate a thiazolidinedione such as pioglitazone; pasireotide-induced hyperglycemia is driven by peripheral insulin resistance from excess cortisol, and insulin sensitizers are the preferred pharmacological class to restore glucose uptake in skeletal muscle.
E)Initiate a glucagon-like peptide-1 (GLP-1) receptor agonist; pasireotide inhibits insulin secretion and glucagon suppression through somatostatin receptor activation on pancreatic alpha and beta cells, and GLP-1 receptor agonists are the preferred agents because they stimulate insulin secretion and suppress glucagon through GLP-1R-mediated mechanisms that are not blocked by somatostatin receptor activation.
ANSWER: E
Rationale:
Pasireotide-induced hyperglycemia occurs in over 70% of Cushing disease patients and results from somatostatin receptor-mediated suppression of pancreatic insulin secretion (SSTR5 on beta cells) and impaired glucagon suppression (SSTR2 on alpha cells), producing a state of relative insulin deficiency and impaired counter-regulatory glucagon control. Because somatostatin receptor activation directly suppresses insulin release, agents that depend on intact insulin secretion through insulin secretagogue mechanisms (sulfonylureas, meglitinides, DPP-4 inhibitors) have attenuated efficacy. GLP-1 receptor agonists stimulate insulin secretion and suppress glucagon through GLP-1R-mediated intracellular pathways (cAMP/PKA signaling in beta cells) that are distinct from and not antagonized by somatostatin receptor activation; they therefore retain efficacy in the presence of pasireotide and are the preferred first-line agents for pasireotide-induced hyperglycemia in clinical guidelines. Insulin may be required for severe hyperglycemia but GLP-1 receptor agonists represent the preferred oral/injectable non-insulin approach.
Option A is incorrect because the primary driver of pasireotide-induced hyperglycemia is impaired insulin secretion and glucagon dysregulation, not increased hepatic glucose output through AMPK suppression; while metformin may have some benefit as adjunct therapy, its mechanism does not directly address the pancreatic defect and it is not the preferred first-line agent in guidelines for this indication.
Option B is incorrect because sulfonylureas stimulate insulin release by closing ATP-sensitive potassium (KATP) channels on beta cells, a mechanism downstream of glucose sensing; however, because somatostatin receptor activation by pasireotide inhibits insulin exocytosis through Gi-coupled cAMP reduction at a step downstream of KATP channel closure, sulfonylurea-driven insulin release is partially blunted by concurrent pasireotide — making this class less effective than GLP-1 receptor agonists in this setting.
Option C is incorrect because while SGLT2 inhibitors do lower glucose through an insulin-independent renal mechanism, they are not the preferred first-line agent for pasireotide-induced hyperglycemia in published guidelines; GLP-1 receptor agonists address the pathophysiological mechanism more directly.
Option D is incorrect because the primary mechanism of pasireotide-induced hyperglycemia is insulin secretory failure, not peripheral insulin resistance from cortisol excess; thiazolidinediones address insulin resistance and have no mechanism to restore pasireotide-suppressed insulin secretion, making them poorly suited as first-line agents for this specific indication.
21.A 46-year-old woman with persistent Cushing disease after pituitary surgery is to be started on cabergoline as adjunctive medical therapy while awaiting stereotactic radiosurgery. The treating physician notes that the dose required for Cushing disease differs substantially from the dose used for prolactinoma, and that this difference carries a specific monitoring implication. Which of the following correctly describes the cabergoline dosing difference between these two indications and its primary clinical safety implication?
A)Cabergoline doses for Cushing disease are lower than those used for prolactinoma because ACTH-secreting corticotroph adenomas express D2R (dopamine receptor subtype 2) at higher density than lactotroph adenomas, producing a more sensitive pharmacological response at smaller doses; the lower doses carry minimal cardiac safety implications.
B)Cabergoline doses for Cushing disease are substantially higher than those used for prolactinoma — typically 1 to 7 mg per week versus 0.5 to 2 mg per week for prolactinoma — increasing the cumulative dose exposure and thus the relevance of cardiac valvulopathy risk; baseline echocardiography is recommended before starting cabergoline above 2 mg per week for this indication.
C)Cabergoline doses for Cushing disease are identical to those for prolactinoma, but the duration of treatment is longer; the extended duration is what increases cumulative exposure and necessitates annual echocardiography, independent of weekly dose.
D)Cabergoline doses for Cushing disease are titrated based on 24-hour urinary free cortisol (UFC) rather than prolactin levels; the dose-escalation protocol differs because UFC normalization requires 4 to 6 weeks per dose increment, compared with the 2- to 4-week prolactin titration interval.
E)Cabergoline doses in Cushing disease must be lower than those used in prolactinoma because the drug's primary adverse effect at high doses — adrenal insufficiency — is potentiated by the concurrent cortisol lowering that occurs as the D2R-mediated ACTH suppression takes effect.
ANSWER: B
Rationale:
The dose of cabergoline required to produce clinically meaningful UFC reduction in Cushing disease is substantially higher than the dose that normalizes prolactin in prolactinoma. For prolactinoma, most patients respond at 0.5 to 2 mg per week; for Cushing disease, published series report dose requirements of 1 to 7 mg per week, with a median effective dose often above 2 mg per week. This difference is pharmacologically explained by the fact that corticotroph adenoma D2R expression is variable and often lower than in lactotroph adenomas, requiring higher receptor occupancy to achieve sufficient ACTH suppression. The higher weekly doses translate to greater cumulative cabergoline exposure, which is the principal driver of cardiac valvulopathy risk — recall that valvulopathy was originally described at Parkinson disease doses (3 to 6 mg per day) and is mediated by 5-HT2B receptor activation on valve fibroblasts. The relevant monitoring implication is that baseline echocardiography is recommended before starting cabergoline at doses above 2 mg per week for this indication, with periodic surveillance during treatment.
Option A is incorrect because D2R expression in corticotroph adenomas is generally lower and more variable than in prolactinomas, requiring higher rather than lower doses to achieve adequate ACTH suppression; the dose relationship is the opposite of what is described.
Option C is incorrect because the doses for Cushing disease are not identical to those for prolactinoma — higher weekly doses, not just longer duration, are required; the valvulopathy risk is driven by both dose and duration, but the primary monitoring trigger is dose exceeding 2 mg per week, not duration alone.
Option D is incorrect because while UFC is the pharmacodynamic monitoring parameter for cabergoline in Cushing disease (analogous to prolactin in prolactinoma), the titration interval described — 4 to 6 weeks per UFC-based increment — is not a distinguishing pharmacological feature that generates the safety monitoring implication asked about in this question.
Option E is incorrect because adrenal insufficiency is not a primary adverse effect of cabergoline in Cushing disease; it is a risk of effective steroidogenesis inhibitors; cabergoline lowers ACTH (and thereby cortisol) only partially in most patients, and adrenal insufficiency from cabergoline alone is uncommon at the doses used.
22.A 57-year-old woman with Cushing syndrome on mifepristone therapy returns for follow-up. She has lost 8 kg, her blood pressure has normalized, and her fasting glucose has decreased from 210 to 96 mg/dL. However, her serum cortisol is markedly elevated and her 24-hour urinary free cortisol (UFC) is above the upper limit of normal. A colleague suggests that the high UFC indicates treatment failure and recommends adding a steroidogenesis inhibitor. Which of the following best guides the correct interpretation of this monitoring data and the most appropriate clinical response?
A)The elevated UFC confirms treatment failure; mifepristone has lost efficacy, likely due to upregulation of glucocorticoid receptor (GR) expression that overcomes receptor blockade; adding a steroidogenesis inhibitor to lower cortisol production is the correct next step.
B)The elevated UFC indicates that mifepristone has developed pharmacokinetic resistance through CYP3A4 autoinduction; increased mifepristone clearance has reduced plasma drug concentrations, allowing UFC to rise despite initial clinical response; plasma mifepristone levels should be checked before modifying therapy.
C)is above the upper limit of normal. A colleague suggests that the high UFC indicates treatment failure and recommends adding a steroidogenesis inhibitor. Which of the following best guides the correct interpretation of this monitoring data and the most appropriate clinical response? A) The elevated UFC confirms treatment failure; mifepristone has lost efficacy, likely due to upregulation of glucocorticoid receptor (GR) expression that overcomes receptor blockade; adding a steroidogenesis inhibitor to lower cortisol production is the correct next step. B) The elevated UFC indicates that mifepristone has developed pharmacokinetic resistance through CYP3A4 autoinduction; increased mifepristone clearance has reduced plasma drug concentrations, allowing UFC to rise despite initial clinical response; plasma mifepristone levels should be checked before modifying therapy. C) The elevated UFC is consistent with adrenal insufficiency on mifepristone; paradoxically, extreme cortisol excess overwhelms the glucocorticoid receptor blockade and produces adrenal suppression, and the patient should be evaluated with a cosyntropin stimulation test before further management decisions.
D)The elevated cortisol and UFC are the expected pharmacodynamic consequence of mifepristone therapy and do not indicate treatment failure; GR blockade eliminates cortisol's negative feedback on the hypothalamic-pituitary-adrenal (HPA) axis, causing compensatory rises in ACTH and cortisol that render these biochemical markers uninterpretable as efficacy endpoints; treatment success is assessed using clinical endpoints — glucose control, blood pressure, weight, and resolution of cushingoid features — all of which have improved in this patient, confirming an effective response.
E)The elevated UFC suggests that mifepristone is working too effectively — over-blockade of peripheral GR has produced a reflex HPA axis overshoot, and the drug dose should be reduced by 50% to prevent the cortisol elevation from eventually overcoming receptor blockade and producing a cortisol toxicity rebound.
ANSWER: D
Rationale:
Mifepristone is a GR antagonist that blocks cortisol signaling at peripheral tissues without reducing cortisol secretion; it does not lower serum cortisol or UFC. Because GR blockade at the hypothalamus and pituitary eliminates cortisol's negative feedback on the HPA axis, ACTH and cortisol levels predictably rise during mifepristone therapy — this is the expected and unavoidable pharmacodynamic consequence of receptor blockade, not a sign of treatment failure or worsening disease. Serum cortisol, UFC, and ACTH are therefore uninterpretable as efficacy endpoints in patients on mifepristone. Treatment adequacy is assessed using clinical and metabolic endpoints: glucose control (HbA1c, fasting glucose), blood pressure, body weight, resolution of cushingoid features (facial plethora, striae, fat redistribution), and psychiatric symptoms. In this patient, the improvement in all clinical metrics — glucose normalization, blood pressure normalization, 8 kg weight loss — indicates a clinically effective response. Adding a steroidogenesis inhibitor based on elevated UFC would be inappropriate and potentially dangerous, as the combined effect of GR blockade plus reduced cortisol synthesis would greatly increase the risk of adrenal insufficiency.
Option A is incorrect because elevated UFC does not indicate mifepristone treatment failure; the elevated cortisol is the expected pharmacodynamic response to GR blockade, and GR upregulation overcoming blockade is not the mechanism; the clinical improvement confirms efficacy.
Option B is incorrect because CYP3A4 autoinduction by mifepristone has not been established as a mechanism of pharmacokinetic resistance in clinical practice; mifepristone is a CYP3A4 substrate and also inhibits CYP3A4 at clinical doses, making autoinduction of its own clearance unlikely; and the clinical response endpoints are the relevant efficacy measures, not plasma drug levels.
Option C is incorrect because adrenal insufficiency on mifepristone presents with clinical signs — hypotension, fatigue, nausea, hyponatremia — not with elevated UFC; elevated UFC in this context is the expected pharmacodynamic response, not a marker of adrenal insufficiency, which is assessed clinically rather than biochemically in mifepristone-treated patients.
Option E is incorrect because there is no established concept of mifepristone GR over-blockade causing HPA axis overshoot requiring dose reduction based on cortisol or UFC levels; dose adjustments of mifepristone are guided by clinical response and tolerability, not by the degree of cortisol elevation, which is expected to rise with any effective GR blockade.